Особенности назначения ингибиторов протонной помпы у коморбидных пациентов с сердечно-сосудистыми заболеваниями и гастроэзофагеальной рефлюксной болезнью: фармакокинетические основания для выбора

1. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study. Lancet. 2012;380(9836):37–43.

PMID: 22579043. https://doi.org/10.1016/S0140-6736(12)60240-2

2. Garin N, Koyanagi A, Chatterji S, Tyrovolas S, Olaya B, Leonardi M et al. Global multimorbidity patterns: a cross-sectional, population-based, multi-country study. J Gerontol A Biol Sci Med Sci. 2016;71(2):205–14.

PMID: 26419978. PMCID: PMC5864156. https://doi.org/10.1093/gerona/glv128

3. Драпкина О.М., Концевая А.В., Калинина А.М., Авдеев С.Н., Агальцов М.В., Алексеева Л.И. с соавт. Коморбидность пациентов с хроническими неинфекционными заболеваниями в практике врача-терапевта. Евразийское руководство. Кардиоваскулярная терапия и профилактика. 2024;23(3):113–418. (Drapkina OM, Kontsevaya AV, Kalinina AM, Avdeev SN, Agaltsov MV, Alekseeva LI et al. Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2024;23(3):113–418 (In Russ.)).

EDN: AVZLPJ. https://doi.org/10.15829/1728-8800-2024-3996

4. Шульпекова Ю.О. Применение рабепразола в практике гастроэнтеролога. Медицинский совет. 2016;(14):26–31. (Shulpekova YuO. Use of rabeprazol in practice of gastroenterologist. Meditsinskiy sovet = Medical Council. 2016;(14):26–31 (In Russ.)).

EDN: WTSGDV. https://doi.org/10.21518/2079-701X-2016-14-26-31

5. Relling MV, Klein TE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Caudle KE. The Clinical Pharmacogenetics Implementation Consortium: 10 years later. Clin Pharmacol Ther. 2020;107(1):171–75.

PMID: 31562822. PMCID: PMC6925644. https://doi.org/10.1002/cpt.1651

6. Teragawa H, Oshita C, Ueda T. History of gastroesophageal reflux disease in patients with suspected coronary artery disease. Heart Vessels. 2019;34(10):1631–38.

PMID: 30993440. https://doi.org/10.1007/s00380-019-01413-1

7. Chen CH, Lin CL, Kao CH. Association between gastroesophageal reflux disease and coronary heart disease: A nationwide population-based analysis. Medicine (Baltimore). 2016;95(27):e4089.

PMID: 27399102. PMCID: PMC5058831. https://doi.org/10.1097/MD.0000000000004089

8. Селиванова Г.Б., Потешкина Н.Г. Коморбидный пациент с гастроэзофагеальной рефлюксной болезнью: особенности выбора ингибитора протонной помпы. Медицинский совет. 2025;19(8):56–63. (Selivanova GB, Poteshkina NG. Comorbid patient with gastroesophageal reflux disease: Features of the choice of proton pump inhibitor. Meditsinskiy sovet = Medical Council. 2025;19(8):56–63 (In Russ.)).

EDN: TLOPHK. https://doi.org/10.21518/ms2025-238

9. Трухан Д.И., Деговцов Е.Н., Мазуров А.Л. Выбор ингибитора протонной помпы с учетом мультиморбидности: фокус на рабепразол. Медицинский совет. 2019;(3):34–42. (Trukhan DI, Degovtsov EN, Mazurov AL. Choice of protonic pump inhibitor with regard to multimorbidity: A focus on rabeprazol. Meditsinskiy sovet = Medical Council. 2019;(3):34–42 (In Russ.)).

EDN: ZFBEYH. https://doi.org/10.21518/2079-701X-2019-3-34-42

10. Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 genotype and clopidogrel therapy. Clin Pharmacol Ther. 2022;112(5):959–67.

PMID: 35034351. PMCID: PMC9287492. https://doi.org/10.1002/cpt.2526

11. Рута А.В., Лучинина Е.В., Шелехова Т.В., и др. Связь генотипов CYP2C19 с особенностями фармакокинетики и фармакодинамики ингибиторов протонной помпы: обзор литературы. Южно-Российский журнал терапевтической практики. 2024;5(1):15–22. (Ruta AV, Luchinina EV, Shelekhova TV, Luchinin EA, Zaitseva MR. Relationship between CYP2C19 genotypes and proton pump inhibitorsʹs pharmacokinetics and pharmacodynamics: Review. Yuzhno-Rossiyskiy zhurnal terapevticheskoy praktiki = South Russian Journal of Therapeutic Practice. 2024;5(1):15–22 (In Russ.)).

EDN: LXKXVT. https://doi.org/10.21886/2712-8156-2024-5-1-15-22

12. Абдуллаев Ш.П., Аметов А.С., Боярко А.В., Денисенко Н.П., Денисова Ю.В., Дмитренко Д.В. с соавт. Прикладная фармакогенетика. Монография. Под ред. Д.А. Сычева. М.: ООО «Издательство «Триада». 2021; 496 с. (Abdullaev ShP, Ametov AS, Boyarko AV, Denisenko NP, Denisova YuV, Dmitrenko DV, et al. Applied pharmacogenetics. Monograph. Ed. by Sychev DA. Moscow: Triada Publishing House LLC. 2021; 496 pp. (In Russ.)).

ISBN: 978-5-94789-982-5. EDN: PXWCTD.

13. Qiao HL, Hu YR, Tian X, Jia LJ, Gao N, Zhang LR, Guo YZ. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur J Clin Pharmacol. 2006;62(2):107–12.

PMID: 16402242. https://doi.org/10.1007/s00228-005-0063-1

14. Денисенко Н.П., Сычев Д.А., Сизова Ж.М., Рожков А.В., Кондрашов А.В.. Влияние полиморфизмов CYP2C19 на эффективность тройной эрадикационной терапии на основе ИПП у пациентов-славян с язвенной болезнью: мета-анализ. Экспериментальная и клиническая гастроэнтерология. 2016;(11):11–16. (Denisenko NP, Sychev DA, Sizova ZhM, Rozhkov AV, Kondrashov AV. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple eradication therapy in slavic patients with peptic ulcers: A meta-analysis. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2016;(11):11–16 (In Russ.)). EDN: WXQEVD.

15. Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: A critical review. Ther Adv Drug Saf. 2018;10:2042098618809927.

PMID: 31019676. PMCID: PMC6463334. https://doi.org/10.1177/2042098618809927

16. Park S, Hyun YJ, Kim YR, Lee JH, Ryu S, Kim JM et al. Effects of CYP2C19 genetic polymorphisms on PK/PD responses of omeprazole in Korean healthy volunteers. J Korean Med Sci. 2017;32(5):729–36.

PMID: 28378544. PMCID: PMC5383603. https://doi.org/10.3346/jkms.2017.32.5.729

17. Gawronska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M, Gornik W, Kaldonska M, Drozdzik M. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteer. Eur J Clin Pharmacol. 2012;68(9):1267–74.

PMID: 22418828. PMCID: PMC3419350. https://doi.org/10.1007/s00228-012-1252-3

18. Chua D, Bolt J, Lo A. Clopidogrel and proton pump inhibitors: A new drug interaction? Can J Hosp Pharm. 2010;63(1):47–50.

PMID: 22478955. PMCID: PMC2832571. https://doi.org/10.4212/cjhp.v63i1.869

19. Zhang H, Ragueneau-Majlessi I, Levy RH. Interaction between clopidogrel and proton pump inhibitors: Hypothesis to explain multifactorial CYP2C19 inhibition. Drug Metab Lett. 2009;3(4):287–89.

PMID: 19995331. https://doi.org/10.2174/187231209790218136

20. Frontiers of Gastrointestinal Research. Proton pump inhibitors: A balanced view. Ed. by Chiba T, Malfertheiner P, Satoh H. Basel: Karger. 2013.

ISBN electronic: 978-3-318-02416-6. ISBN print: 978-3-318-02415-9. https://doi.org/10.1159/isbn.978-3-318-02416-6

21. Заборовский А.В., Маев И.В., Андреев Д.Н., Тарарина Л.А. Плейотропные эффекты рабепразола и их роль в лечении пациентов с кислотозависимыми заболеваниями. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(3):18–26. (Zaborovsky AV, Mayev IV, Andreyev DN, Tararina LA. Pleiotropic effects of rabeprazole at acid-related diseases. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, and Coloproctology. 2017;27(3):18–26 (In Russ.)). EDN: WULBSL.

22. Sharma RK, Reddy HK, Sharma RK, Moazazi M, Elango L, Singh VN et al. The interaction between clopidogrel and proton pump inhibitors (PPI): Is there any clinical relevance? Clin Pharmacol. 2010;2:155–62.

PMID: 22291500. PMCID: PMC3262372. https://doi.org/10.2147/CPAA.S9807

23. Карева Е.Н. Фармакогенетическое управление эффективностью и безопасностью ингибиторов протонных помп. РМЖ. 2021;29(4):68–73. (Kareva EN. Pharmacogenetic management concerning efficacy and safety of proton-pump inhibitors. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2021;29(4):68–73 (In Russ.)). EDN: PVVLOW.

24. Duarte GJ, Lopez J, Sosa F, Molina G, Shaban M, Mark J et al. Proton pump inhibitors and cardiovascular risk: A critical review. Future Cardiol. 2024;20(14):779–94.

PMID: 39466134. PMCID: PMC11622795. https://doi.org/10.1080/14796678.2024.2412910

25. Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther. 2020;109(6):1417–23.

PMID: 32770672. PMCID: PMC7868475. https://doi.org/10.1002/cpt.2015

26. Трухан Д.И., Гришечкина И.А. Актуальные аспекты антисекреторной терапии гастроэзофагеальной рефлюксной болезни. Медицинский совет. 2015;(15):28–35. (Trukhan DI, Grishechkina IA. Actual aspects of anti-secretor therapy of gastroesophageal reflux disease. Meditsinskiy sovet = Medical Council. 2015;(15):28–35 (In Russ.)).

EDN: ZQTKBD. https://doi.org/10.21518/2079-701X-2017-15-28-35

27. Trukhan D.I. Topical drug interactions: in focus proton pump inhibitors and clopidogrel. Consilium Medicum. - 2017; 19 (8.1. Gastroenterology): 45–48.

28. Ивашкин В.Т., Маев И.В., Трухманов А.С., Баранская Е.К., Дронова О.Б., Зайратьянц О.В. с соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(4):70–95. (Ivashkin VT, Maev IV, Trukhmanov AS, Baranskaya YeK, Dronova OB, Zayratyants OV et al. Diagnostics and treatment of gastroesophageal reflux disease: Clinical guidelines of the Russian Gastroenterological Association. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, and Coloproctology. 2017;27(4):70–95 (In Russ.)). EDN: ZIDXIR.

29. Лопина О.Д., Нургалиева Б.К., Лапина Т.Л. Актуальные тенденции в лечении кислотозависимых заболеваний: клиническая эффективность и безопасность рабепразола. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(4):55–63. (Lopina OD, Nurgalieva BK, Lapina TL. Current trends in treatment for acid-dependent diseases: Clinical efficacy and safety of rabeprazole. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, and Coloproctology. 2021;31(4):55–63 (In Russ.)).

EDN: VBWZFC. https://doi.org/10.22416/1382-4376-2021-31-4-55-63

30. Funck-Brentano C, Szymezak J, Steichen O, Ducint D, Molimard M, Remones V et al. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Arch Cardiovasc Dis. 2013;106(12):661–71.

PMID: 24246616. https://doi.org/10.1016/j.acvd.2013.09.002

31. Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T et al. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. J Thromb Thrombolysis. 2017;43(3):333–42.

PMID: 27981489. https://doi.org/10.1007/s11239-016-1460-2

32. Ahn JH, Park Y, Bae JS, Jang JY, Kim KH, Kang MG et al. Influence of rabeprazole and famotidine on pharmacodynamic profile of dual antiplatelet therapy in clopidogrel-sensitive patients: The randomized, prospective, PROTECT trial. Platelets. 2020;31(3):329–36.

PMID: 31037994. https://doi.org/10.1080/09537104.2019.1609667

33. El-Halabi MM, Zgheib N, Mansour NM, Malli A, Ghaith OA, Mahfouz R et al. CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel. J Cardiovasc Pharmacol. 2013;62(1):41–49.

PMID: 23474843. https://doi.org/10.1097/FJC.0b013e31828ecf44

34. Lanas-Gimeno A, Hijos G, Lanas A. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opin Drug Saf. 2019;18(11):1043–53.

PMID: 31498687. https://doi.org/10.1080/14740338.2019.1664470

35. Corsonello A, Lattanzio F, Bustacchini S, Garasto S, Cozza A, Schepisi R et al. Adverse events of proton pump inhibitors: Potential mechanisms. Curr Drug Metab. 2018;19(2):142–54.

PMID: 29219052. https://doi.org/10.2174/1389200219666171207125351

36. Ивашкин В.Т., Маев И.В., Трухманов А.С., Шептулин А.А., Симаненков В.И., Лапина Т.Л. с соавт. Депрескрайбинг ингибиторов протонной помпы и выбор оптимального препарата данной группы (по результатам научного форума, состоявшегося в рамках XXVI Объединенной российской гастроэнтерологической недели). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(6):7–18. (Ivashkin VT, Maev IV, Trukhmanov AS, Sheptulin AA, Simanenkov VI, Lapina TL et al. Deprescribing and optimal selection of proton pump inhibitors (contributions of the 26th United Russian Gastroenterology Week). Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, and Coloproctology. 2020;30(6):7–18 (In Russ.)).

EDN: KMMASC. https://doi.org/10.22416/1382-4376-2020-30-6-7-18

37. Niu Q, Wang Z, Zhang Y, Wang J, Zhang P, Wang C et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: A meta-analysis. J Cardiovasc Pharmacol Ther. 2016;22(2):142–52.

PMID: 27512080. https://doi.org/10.1177/1074248416663647

38. Mosholder AD, Hada M, Leishear K. Proton-pump inhibitors and cardiovascular adverse events: A meta-analysis of randomized controlled trials. Am J Gastroenterol. 2025;120(2):362–69.

PMID: 39207289. https://doi.org/10.14309/ajg.0000000000003058

39. Padhi BK, Khatib MN, Zahiruddin QS, Rustagi S, Sharma RK, Sah R et al. Adverse cardiovascular outcomes associated with proton pump inhibitor use after percutaneous coronary intervention: A systematic review and meta-analysis. BMC Cardiovascular Disorders. 2024;24(1):372.

PMID: 39020285. PMCID: PMC11253415. https://doi.org/10.1186/s12872-024-04029-0

40. Ai MY, Chen YZ, Kuo CL, Chang WL. A network meta-analysis: Evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients. Front Cardiovasc Med. 2024;11:1385318.

PMID: 39114562. PMCID: PMC11303300. https://doi.org/10.3389/fcvm.2024.1385318

41. NHS Specialist Pharmacy Service. Using clopidogrel with proton pump inhibitors (PPIs). 2023. URL: https://www.sps.nhs.uk/articles/using-clopidogrel-with-proton-pump-inhibitors-ppis/ (date of access – 24.06.2026).

42. Dalal J, Dutta AL, Hiremath J, Iyengar SS, Mohan JC, Ooman A et al. Cardiovascular compatibility of proton pump inhibitors: Practice recommendations. Cardiol Ther. 2023;12(4):557–70.

PMID: 37947939. PMCID: PMC10703758. https://doi.org/10.1007/s40119-023-00338-1

43. Рута А.В., Шелехова Т.В., Лучинина Е.В., Зайцева М.Р., Рубцов А.А., Авакян А.М. с соавт. Фармакогенетика ингибиторов протонной помпы: от теории к персонализированной клинической практике (обзор литературы). Научно-медицинский вестник Центрального Черноземья. 2025;26(4):41–57. (Ruta AV, Shelekhova TV, Luchinina EV, Zaitseva MR, Rubtsov AA, Avakyan AM et al. Pharmacogenetics of proton pump inhibitors: From theory to personalized clinical practice (review). Nauchno-meditsinskiy vestnik Tsentral’nogo Chernozem’ya = Medical Scientific Bulletin of Central Chernozemye. 2025;26(4):41–57 (In Russ.)).

EDN: JBPFDP. https://doi.org/10.18499/1990-472X-2025-26-4-41-57

44. US Food & Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. URL: https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm (date of access – 24.06.2026).